Skip to main content
Premium Trial:

Request an Annual Quote

Immusol Signs Up for Celera Discovery System

SAN FRANCISCO, Nov. 8 – Biopharmaceutical company Immusol signed a multi-year subscription to Celera Genomics’ Discovery System, the companies announced Thursday.

Financial terms of the agreement between Immusol, based in San Diego, Calif., and Rockville, Md.-based Celera, were not disclosed.

“The combination of the Celera system with our Inverse Genomics platform will greatly expand our capacity to identify and develop therapeutic targets and compounds both for partnerships and internal screening efforts,” Jack Barber, vice president of research and development at Immusol, said in a statement.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.